vgoradia commited on
Commit
8dada60
·
verified ·
1 Parent(s): 44d0475

Update README.md

Browse files
Files changed (1) hide show
  1. README.md +127 -13
README.md CHANGED
@@ -1,23 +1,137 @@
1
  ---
2
  license: apache-2.0
 
 
 
 
 
 
 
 
 
 
3
  ---
4
- ---
5
- license: apache-2.0
6
- ---
7
 
8
- # MolScreen
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
 
10
- Graph neural network for early-stage molecular toxicity screening.
11
 
12
- Trained on the Tox21 dataset (7,823 compounds, 12 toxicity endpoints).
13
- Test mean ROC-AUC: 0.8525.
 
 
 
 
 
14
 
15
- **Live app:** https://mol-screen-32jrti5gpuajmd8wse5u3f.streamlit.app
16
- **GitHub:** https://github.com/vgoradia/mol-screen
17
 
18
- ## Usage
19
 
20
- Load with PyTorch:
21
 
22
- model = MolScreenGNN()
23
- model.load_state_dict(torch.load('molscreen_best.pt'))
 
1
  ---
2
  license: apache-2.0
3
+ tags:
4
+ - molecular-toxicity
5
+ - drug-discovery
6
+ - graph-neural-network
7
+ - cheminformatics
8
+ - tox21
9
+ - interpretability
10
+ - gineconv
11
+ language:
12
+ - en
13
  ---
 
 
 
14
 
15
+ # MolScreen: GNN for Molecular Toxicity Screening
16
+
17
+ **MolScreen** is a Graph Isomorphism Network with Edge features (GINEConv) trained on the Tox21 dataset for multi-task molecular toxicity prediction. It combines GNN-based predictions with gradient-based atom attribution and LLM-generated triage notes to make toxicity screening interpretable and actionable.
18
+
19
+ Developed by Veer Goradia. Accepted to **NeurIPS 2026 AIDaR Workshop** (Paris, December 2026).
20
+
21
+ ## Model Description
22
+
23
+ Drug toxicity is one of the leading causes of late-stage clinical trial failure, costing billions in wasted development. MolScreen addresses two key gaps in existing approaches: most models give a probability but no explanation, and none integrate a human-readable summary for non-expert decision makers.
24
+
25
+ **Architecture:**
26
+ - GINEConv backbone — uses edge features (bond type, aromaticity, conjugation) that plain GCN/GIN discard
27
+ - Multi-task classification across 12 Tox21 endpoints simultaneously
28
+ - Masked BCE loss for Tox21's missing labels (5,800–7,200 valid labels per task)
29
+ - Gradient-based atom attribution: highlights which molecular substructures drove the prediction
30
+ - LLM triage layer: generates a 3-sentence actionable summary (SMILES + flagged probabilities + top-3 attributed atoms per task)
31
+
32
+ **Total parameters:** ~374,000
33
+ **Inference time:** ~0.7 seconds end-to-end (excluding LLM API call)
34
+ **Training time:** ~6 minutes on laptop CPU (60 epochs)
35
+
36
+ ## Performance
37
+
38
+ ### Random Split (10-seed validation)
39
+ | Metric | Value |
40
+ |--------|-------|
41
+ | Mean ROC-AUC | 0.8442 ± 0.0073 |
42
+
43
+ ### Scaffold Split (10-seed validation)
44
+ | Metric | Value |
45
+ |--------|-------|
46
+ | Mean ROC-AUC | 0.7716 ± 0.0036 |
47
+
48
+ ### Baseline Comparison (Scaffold Split)
49
+ | Model | ROC-AUC |
50
+ |-------|---------|
51
+ | **MolScreen (GINEConv)** | **0.7716** |
52
+ | Plain GCN | 0.7481 |
53
+ | Random Forest (Morgan FP) | 0.7465 |
54
+ | XGBoost (Morgan FP) | 0.7378 |
55
+ | Plain GIN | 0.7249 |
56
+ | Chen et al. SSL-GCN (2021) | 0.7570 |
57
+
58
+ MolScreen beats the best non-pretrained baseline (GCN) by 2.4 points. The GINEConv edge-awareness advantage over plain GIN (+4.7 points) confirms that bond-level features matter for generalization.
59
+
60
+ ### Per-Task ROC-AUC (Random Split, representative run)
61
+ | Endpoint | AUC |
62
+ |----------|-----|
63
+ | NR-AR | 0.8518 |
64
+ | NR-AR-LBD | 0.9119 |
65
+ | NR-AhR | 0.8938 |
66
+ | NR-Aromatase | 0.8788 |
67
+ | NR-ER | 0.7486 |
68
+ | NR-ER-LBD | 0.8400 |
69
+ | NR-PPAR-gamma | 0.8918 |
70
+ | SR-ARE | 0.8125 |
71
+ | SR-ATAD5 | 0.8762 |
72
+ | SR-HSE | 0.7374 |
73
+ | SR-MMP | 0.9156 |
74
+ | SR-p53 | 0.8713 |
75
+
76
+ ## Training Data
77
+
78
+ - **Dataset:** Tox21 (7,823 valid compounds, 12 toxicity endpoints)
79
+ - **Assay categories:** Nuclear receptor panel (NR-*) and stress response panel (SR-*)
80
+ - **Class imbalance:** 2.6%–16% positive rate per task
81
+ - **Splits:** Random split (80/10/10) and scaffold split (chemotype-based, harder generalization test)
82
+
83
+ ## Intended Use
84
+
85
+ - Early-stage drug candidate toxicity screening
86
+ - Prioritizing which compounds advance to lab testing
87
+ - Interpretability analysis via atom-level attribution maps
88
+ - Research on GNN-based molecular property prediction
89
+
90
+ ## How to Use
91
+
92
+ ```python
93
+ import torch
94
+ from huggingface_hub import hf_hub_download
95
+
96
+ # Load model from HuggingFace
97
+ model_path = hf_hub_download(repo_id="vgoradia/MolScreen", filename="molscreen_best.pt")
98
+ model = torch.load(model_path, map_location='cpu')
99
+ model.eval()
100
+
101
+ # Or try the live Streamlit app — no code needed
102
+ ```
103
+
104
+ ## Live Demo
105
+
106
+ Try the interactive app (draw a molecule, get toxicity predictions + atom attribution):
107
+ [MolScreen Streamlit App](https://mol-screen-32jrti5gpuajmd8wse5u3f.streamlit.app)
108
+
109
+ ## Publications & Acceptances
110
+
111
+ - **NeurIPS 2026 AIDaR Workshop** — ACCEPTED (poster, Paris, December 12 2026)
112
+ - **BIBM 2026 AIPBDA Workshop** — SUBMITTED (Paper ID S49203)
113
+ - **Harvard HSRC 2026** — ACCEPTED (virtual, October 17-18 2026)
114
+ - **Regeneron STS 2027** — SUBMITTED (November 2026)
115
+ - AAAI-27 AISI Track — Submitted (Submission #598)
116
+
117
+ ## GitHub
118
+
119
+ [github.com/vgoradia/mol-screen](https://github.com/vgoradia/mol-screen)
120
 
121
+ ## Citation
122
 
123
+ @misc{goradia2026molscreen,
124
+ title={MolScreen: Interpretable Multi-Task Molecular Toxicity Screening
125
+ with Graph Neural Networks and LLM Triage},
126
+ author={Goradia, Veer},
127
+ year={2026},
128
+ note={NeurIPS 2026 AIDaR Workshop}
129
+ }
130
 
131
+ ## License
 
132
 
133
+ Apache 2.0
134
 
135
+ ## Contact
136
 
137
+ Veer Goradia · vgoradia07@gmail.com